These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22463610)

  • 21. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
    Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CB1 antagonists for obesity--what lessons have we learned from rimonabant?
    Di Marzo V; Després JP
    Nat Rev Endocrinol; 2009 Nov; 5(11):633-8. PubMed ID: 19844251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
    Giraldo J
    Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
    Gadde KM; Allison DB
    Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
    [No Abstract]   [Full Text] [Related]  

  • 29. CB(1) receptor antagonism: biological basis for metabolic effects.
    Di Marzo V
    Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats.
    Varga B; Kassai F; Gyertyán I
    Pharmacol Biochem Behav; 2012 Dec; 103(2):425-30. PubMed ID: 23026059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rimonabant on weight and cardiometabolic risk factors.
    Gadde KM
    JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
    [No Abstract]   [Full Text] [Related]  

  • 32. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
    Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sleep disorders associated with treatment with rimonabant].
    Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
    Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
    Meye FJ; Trezza V; Vanderschuren LJ; Ramakers GM; Adan RA
    Mol Psychiatry; 2013 Dec; 18(12):1294-301. PubMed ID: 23070073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripherally restricted CB1 receptor blockers.
    Chorvat RJ
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP; Ross R; Boka G; Alméras N; Lemieux I;
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.